This is how the playbook works when it works perfectly. In December 2023, Gilead Sciences signs a partnership with Tubulis worth up to $465 million to co-develop a topoisomerase I inhibitor-based ADC. In October 2025, Tubulis presents ESMO data showing TUB-040 hit a 59% overall response rate in platinum-resistant ovarian cancer — heavily pretreated, biomarker-unselected patients. Today? Gilead is buying the whole company for up to $5 billion.
Let that timeline sink in. Partnership to acquisition in roughly two years. And Gilead isn’t just buying a drug — they’re buying the factory. Post-close (expected Q2 2026), Tubulis becomes Gilead’s dedicated ADC innovation hub in Munich, with the proprietary P5 conjugation technology and Tubutecan linker-payload platform that made these assets possible in the first place.
From partnership to buyout — the Tubulis arc
2019
Tubulis spins out of two German research institutes in Munich
Dec 2023
Gilead partners with Tubulis — deal worth up to $465M
Oct 2025
TUB-040 posts 59% ORR in platinum-resistant ovarian cancer at ESMO
Oct 2025
Closes €344M Series C — largest for a European biotech and private ADC company
Apr 2026
Gilead acquires Tubulis — $3.15B upfront + $1.85B milestones
The deal structure: $3.15 billion upfront, plus up to $1.85 billion in milestones. For context, Tubulis had just closed a €344 million Series C in October 2025 — the largest Series C ever for a European biotech company and the largest private ADC financing globally — led by Venrock Healthcare with Wellington Management and Ascenta Capital. Those investors had a very short hold period and a very nice return.
What Gilead gets: TUB-040 (NaPi2b-targeted, Phase 1b/2 in ovarian cancer and NSCLC with that FDA Fast Track designation), TUB-030 (5T4-targeted, earlier stage), and critically, the P5 conjugation technology — a site-specific cysteine conjugation approach that achieves a homogeneous DAR of 8 while minimizing premature payload loss. That’s the real prize. Better conjugation chemistry means better ADCs across every future program Gilead builds.
This is also a validation signal for the entire ADC engineering space. We wrote earlier today about ABION rethinking ADC payloads, and yesterday about Stipple Bio raising $100M for precision ADC engineering. Now Gilead drops $5 billion on next-gen ADC conjugation. The message from big pharma is clear: the first generation of ADCs was the proof of concept. The real money is in the second generation — better linkers, better payloads, better engineering. The ADC arms race isn’t slowing down. It’s accelerating.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
